To validate that the in vivo antitumor effect of SST0116CL1 was effectively related to the inhibition of Hsp90, the modulation of selected Hsp90 client proteins was assessed by western blot in tumor xenografts a few hours after the last treatment. This evidence concerns the gene HSP90AA1 and neoplasm.